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Abstract
Background: Triple-negative breast cancer (TNBC), an aggressive disease comprising several subtypes including
basal-like and claudin-low, involves frequent deletions or point mutations in TP53, as well as loss of PTEN. We
previously showed that combined deletion of both tumor suppressors in the mouse mammary epithelium
invariably induced claudin-low-like TNBC. The effect of p53 mutation plus Pten deletion on mammary
tumorigenesis and whether this combination can induce basal-like TNBC in the mouse are unknown.
Methods: WAP-Cre:Ptenf/f:p53lox.stop.lox_R270H composite mice were generated in which Pten is deleted and a
p53-R270H mutation in the DNA-binding domain is induced upon expression of Cre-recombinase in pregnancy-
identified alveolar progenitors. Tumors were characterized by histology, marker analysis, transcriptional profiling
[GEO-GSE75989], bioinformatics, high-throughput (HTP) FDA drug screen as well as orthotopic injection to quantify
tumor-initiating cells (TICs) and tail vein injection to identify lung metastasis.
Results: Combined Pten deletion plus induction of p53-R270H mutation accelerated formation of four distinct
mammary tumors including poorly differentiated adenocarcinoma (PDA) and spindle/mesenchymal-like lesions.
Transplantation assays revealed highest frequency of TICs in PDA and spindle tumors compared with other subtypes.
Hierarchical clustering demonstrated that the PDA and spindle tumors grouped closely with human as well as mouse
models of basal and claudin-low subtypes, respectively. HTP screens of primary PtenΔ:p53Δ vs. PtenΔ:p53R270H spindle
tumor cells with 1120 FDA-approved drugs identified 8-azaguanine as most potent for both tumor types, but found no
allele-specific inhibitor. A gene set enrichment analysis revealed increased expression of a metastasis pathway in
PtenΔ:p53R270H vs. PtenΔ:p53Δ spindle tumors. Accordingly, following tail vein injection, both PtenΔ:p53R270H spindle and
PDA tumor cells induced lung metastases and morbidity significantly faster than PtenΔ:p53Δ double-deletion cells, and
this was associated with the ability of PtenΔ:p53R270H tumor cells to upregulate E-cadherin expression in lung
metastases.
Conclusions: Our results demonstrate that WAP-Cre:Ptenf/f:p53lox.stop.lox_R270H mice represent a tractable model to
study basal-like breast cancer because unlike p53 deletion, p53R270H mutation in the mouse does not skew tumors
toward the claudin-low subtype. The WAP-Cre:Ptenf/f:p53lox.stop.lox_R270H mice develop basal-like breast cancer that is
enriched in TICs, can readily form lung metastasis, and provides a preclinical model to study both basal-like and
claudin-low TNBC in immune-competent mice.
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Background
Breast cancer is a highly heterogeneous disease compris-
ing estrogen receptor alpha (ERα)-positive and HER2/
ERBB2/NEU-positive subtypes as well as triple-negative
breast cancers (TNBCs) that do not express ERα, human
epidermal growth factor 2 (HER2) or the progesterone
receptor. TNBC can be further divided into several add-
itional groups including basal-like and mesenchymal/
claudin-low [1–5]. These tumors contain mutations or
deletion in the tumor suppressor p53 in 60–80 % of
cases [4]. In addition, 35 % of TNBC also show loss of
expression of the tumor suppressor phosphatase and
tensin homolog deleted in chromosome 10 (PTEN).
The latter is a phosphatase that converts phos-
phatidylinositol (3, 4, 5)-trisphosphate (PIP3) into
phosphatidylinositol (4, 5)-disphosphate (PIP2), thereby
antagonizing phoshotidylinositol-3 kinase (PI3K) pathway
activation [6–8]. On the basis of frequency in which each
gene is disrupted alone, combined loss of p53 and Pten in
TNBC is calculated at about 21–28 %. In addition, using
Pten RNA expression and p53 pathway activity it was esti-
mated that 24.4 % of TNBCs are Pten-low, 65.6 % are p53
activity-low, and 18.7 % are both Pten-low and p53 path-
way activity-low [9].
The generation of mice with mutations that occur in
breast cancer offers a window into the mechanisms of
tumor initiation, progression and spread in immune-
competent mice, and provide preclinical models to test
potential new therapies. Deletion of p53 in the mouse
induces diverse tumors as well as claudin-low-like TNBC
[10]. We recently showed that combined deletion of p53
and Pten via mouse mammary tumor virus (MMTV)-
CreNLS or whey acidic protein (WAP)-Cre drivers in-
duces almost exclusively claudin-low TNBC-like tumors
[9]. This suggests that p53 deletion in the mouse pro-
motes mesenchymal-like cancer, which is further accel-
erated by disruption of Pten.
To generate a model for basal-like Pten/p53 mutant
TNBC, we here tested the effect of deleting Pten and ex-
pressing p53R270H mutation in the DNA-binding domain
(DBD) [11]. This and similar mutations in p53 DBD
were shown to act as dominant-negative or gain-of-
function alleles that accelerate metastasis through
multiple mechanisms [12]. Targeted expression of
p53R270H in the mammary epithelium was reported to
induce divergent tumors [13]. Here we show that
WAP-Cre:Ptenf/f:p53lox.stop.lox_R270H composite mice de-
velop spindle-like and poorly differentiated adenocarcin-
oma (PDA) as well as other subtypes. Using microarray
profiling, we found that the spindle and PDA tumors clus-
tered with claudin-low and basal-like breast cancer
(BLBC), respectively, and metastasized to the lung follow-
ing tail vein injection significantly faster than tumors from
WAP-Cre:Ptenf/f:p53f/f double-deletion mice. Thus, WAP-
Cre:Ptenf/f:p53lox.stop.lox_R270H mice provide a preclinical




Animal protocols were approved by the University
Health Network in accordance with the guidelines of the
Canadian Council of Animal Care. WAP-Cre mice [14]
kindly received from Dr. Lothar Hennighausen, National
Institutes of Health (NIH), were crossed with Ptenf/f
mice [15] from Dr. Tak Mak, Princess Margaret Cancer
Centre (PMCC), as described [9], and then further
mated with p53LSLR270H/+ mice [11], which were gener-
ated by Dr. Tyler Jacks, Massachusetts Institute of Tech-
nology (MIT), and obtained through National Cancer
Institute (NCI) Mouse Models of Human Cancers Con-
sortium (MMHCC). Compound mutant mice used in
this study were on a mixed genetic background.
PCR genotyping and deletion analysis
Compound mutant mouse strains utilized in this study
were genotyped as previously described [16, 17]. Dele-
tion of the Ptenf/f allele was detected by polymerase
chain reaction (PCR) using the following primers: For-
ward: 5′GTCACCAGGATGCTTCTGAC3′, Reverse: 5′
ACTATTGAACAGAATCAACCC3′ where Ptenf/f re-
sults in a 335 bp product and PtenΔf/f in an 849 bp prod-
uct. For p53R270H recombination detection, the following
primers were used to yield a wild-type band of 290 bp
and mutant allele of 330 bp: wt Forward: 5′-TTACA-
CATCCAGCCTCTGTGG-3′; mutant Forward: 5′-
AGCTAGCCACCAT GGCTTGAGTAAGTCTGCA-3′;
Reverse: 3′-CTTGGAGACATAGCCACACTG-3′. To
determine the presence of the LSL cassette in p53, the
following primers were used to detect a wild-type band
of 166 bp and mutant allele of 270 bp: Forward: 5′-
AGCCTGCCTAGCTTCCTCAGG-3′; Reverse: 5′-CTT
GGAGACATAGCCACACTG-3.
Primary tumor cell isolation
Tumor tissue was minced with sterile razor blades and
placed in 100 U/ml collagenase/hyaluronidase solution
(StemCell Technology, Vancouver, BC, Canada; number
07912) overnight at 4 °C, and then for 30 min at 37 °C
with occasional mixing. Digested tissues were rinsed
with Hank’s balanced salt solution (Gibco, Carlsbad, CA,
USA) containing 2 % fetal bovine serum (FBS) (HF) and
centrifuged at 1500 rpm for 5 min. Tumor cells were
passed through a 40 mm cell strainer.
Tumorsphere culturing in vitro
Cell suspension of single cell mammary tumor epithelial
cells were plated onto ultra-low attachment plates
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(Corning, Tewksbury, MA, USA; Costar number 3473)
in Dulbecco’s modified Eagle’s medium (DMEM)/F-12
Ham medium (Sigma-Aldrich, St. Louis, MO, USA;
number D8900) containing 20 ng/ml basic fibroblast
growth factor (bFGF) (Sigma-Aldrich; number F0291),
20 ng/ml epidermal growth factor (EGF) (Sigma-Aldrich;
number E9644), 4 μg/ml of heparin (Sigma-Aldrich;
number H4784) and B-27 supplement (1:50 dilution,
Gibco; number 17504-044), and cultured at 37 °C; 5 %
CO2 as described [18]. Spheres were mechanically and
enzymatically dissociated weekly in 0.25X (0.05 %)
Trypsin-EDTA solution (Gibco; number 25300) for
3 min at 37 °C, followed by gentle trituration for 1 min.
To create tumor-derived primary cell lines, tumor-
spheres were plated in tissue culture plates and ex-
panded under adherent conditions.
Orthotopic transplantation and tail vein injection
Cells were transplanted into the number 4 mammary
glands of 3–5-week-old immune-deficient NOD/SCID
female mice as described [19]. Indicated number of cells
were resuspended in 10 μl of media and mixed at 1:1 ra-
tio with 10 μl matrigel (BD Biosciences, Franklin Lakes,
NJ, USA; number 356234) on ice. Samples (total 20 μl)
were then injected into mice under isoflurane anesthesia.
Mice were monitored for tumor formation for up to
6 months. For tail vein injections, tumor-derived cell lines
were dissociated into single cells and 200 μl of 1 × 105
cells/100 μl resuspended in DMEM media injected into
the lateral tail vein.
Histology and immunohistochemistry
Paraffin sections (5 μm thick) were immunostained
using the following antibodies/dilution: p53 (1:200; FL-
393; Santa Cruz Biotechnology Inc., Dallas, TX, USA;
number sc-6243), Ki67 (1:150; Biocare Medical Inc.,
Concord, CA, USA; number CRM325, clone SP6), CK6
(1:200, Covance, Princeton, NJ, USA; number PRB-
169B), CK5 (1:20; NeoMarkers, Fremont, CA, USA;
number XM26), CK14 (1:200; Panomics, Fremont, CA,
USA; number E2624), CK18 (1:200; Fitzgerald Industries
International, Acton, MA, USA number RDI-PR061028),
and vimentin (1:50; Santa Cruz Biotechnology Inc.; num-
ber SC32322) as described [17]. Secondary biotinylated
anti-mouse or anti-rabbit antibodies (Vector Laborator-
ies, Burlingame, CA, USA) were used at 1:200 dilution.
Immunohistochemistry (IHC) was performed using
VECTASTAIN ABC Systems (Vector Laboratories). Sec-
tions were counterstained with methylene green.
RNA isolation, microarray and cluster analysis
Total RNA was extracted using TRIZOL reagent (Invi-
trogen, Burlington, ON, Canada). Microarray analysis
was carried out using Affymetrix Mouse Gene 1.0 ST
with 500 ng of total RNA (Centre for Applied Genomics,
Hospital for Sick Children, Toronto, ON, Canada), and
data deposited in the Gene Expression Omnibus (GEO)
under the accession number GEO:GSE75989. Microarray
data were normalized using the robust multiarray aver-
aging (RMA) method via Partek and log2-transformed
gene expression values were obtained as described [19].
To compare our mouse models with human breast cancer
(BC) and other published models, median-centered values
of our mouse microarray data were integrated with
GSE18229 (human BC) and GSE3165 (mouse models) by
“distance-weighted discrimination” (DWD). The subtypes
of human BCs in GSE18229 were predetermined with
PAM50 and the claudin-low signature [9, 20, 21]. The
DWD-integrated samples were classified by unsupervised
hierarchical clustering (complete linkage) using shared in-
trinsic genes, the basal, luminal, and mesenchymal gene
sets [20], and the claudin-low signature [21]. Values of
gene expression were log2-transformed, median-centered,
and visualized as heat maps by Java TreeView.
GSEA pathway analysis
Gene expression data were analyzed using the gene set en-
richment analysis (GSEA) Preranked method from the
Broad Institute (version 2.2.0, [22]) with parameters set to
1000 gene set permutations. Genes were ordered using
the “limma” package in R to obtain t values corresponding
to each pair-wise comparison with Benjamini and Hoch-
berg's method to control the false discovery rate (FDR).
The gene sets included in the GSEA analyses were
obtained from MSigDB containing BioCarta, KEGG,
Matrisome, Pathway Interaction Database, Reactome, Sig-
maAldrich, Signaling Gateway, Signal Transduction KE,
SuperArray gene sets (c2, v5.0) and the Gene Ontology
(GO) databases (c5, v5.0), updated on March 2015 (http://
www.broadinstitute.org/gsea/downloads.jsp). An enrich-
ment map (version 1.1 of Enrichment Map software
[23], was generated by Cytoscape (version 2.8.3) for
each comparison using enriched gene sets with a
nominal p value < 0.005, FDR < 0.1, and the overlap
coefficient set to 0.5.
Prestwick (FDA-approved) drug screen
High-throughput (HTP) screens of 1120 Food and Drug
Administration (FDA)-approved drugs using a robotic
Biomek FX liquid handler equipped with a pintool for
automated compound dispensing were performed at the
S.M.A.R.T facility, Samuel Lunenfeld Research Institute
as previously described [9]. Cells were seeded onto 384-
well plates, and pinned with chemicals resuspended in
DMSO to reach a final concentration of 1 μM (Prestwick
library, Prestwick Chemical, San Diego, CA, USA). As a
reference for 100 % activity, each plate included wells
with cells treated with vehicle only, and background was
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measured with media in the absence of cells. Alamar
blue (Invitrogen) was added 2 d post-treatment, and cell
viability was read 5 h later. Screen data were normalized
by Z score [24].
MTT viability assay
For validation experiments, cells were seeded in 96-well
plates and treated the following day. At 3 d post-treatment,
20 μL of 2 mg/mL MTT (3-[4,5-dimethylthiazol-2-yl]-2, 5-
diphenyl tetrazolium bromide, Sigma-Aldrich) were added
and incubated for 4 h. MTT/media solution was aspirated
and replaced with DMSO and cell viability was read after
5 min incubation.
Additional statistical analysis
Survival, drug response and IHC data were analyzed
using Mantel-Cox test, non-linear regression and Stu-
dent’s t test, respectively. Tumor-initiating cell (TIC) fre-
quency was calculated using L-cal (www.stemcell.com).
Results
Targeted Pten deletion plus expression of a p53-R270H
mutant in mammary epithelium accelerate mammary
tumorigenesis
WAP-Cre:Ptenf/f:p53lox.stop.lox_R270H/+ composite mice
(WAP-Cre:Ptenf/f:p53lsl_R270H/+ for short) developed
mammary tumors with significantly shorter latency than
parental WAP-Cre:Ptenf/f or WAP-Cre:p53lsl_R270H/+ fe-
males (Fig. 1a). Deletion of Pten and the loxP-stop-loxP
cassette was confirmed by PCR (Fig. 1b). Histology ana-
lysis revealed that WAP-Cre:p53lsl_R270H/+ mice devel-
oped three major tumors types: spindle-like, PDA and
mixed subtypes (Fig. 1c; Additional file 1). Tumor distri-
bution in WAP-Cre:Ptenf/f:p53lsl_R270H/+ mice was more
similar to WAP-Cre:Ptenf/f mice including spindle-like,
PDA, squamous carcinoma, adenomyoepitheliomas (AME)
and mixed tumors. However, the ratio of these tumors var-
ied (Fig. 1c). The spindle and PDA tumors were highly pro-
liferative relative to other types as judged by Ki67
expression and expressed low levels of the myoepithelial
cytokeratin marker, K14 (Fig. 1d). In contrast, the spindle
tumors did not express the luminal marker, K18, whereas
the PDAs showed low/variable expression pattern. We spe-
cifically stained the PDA and spindle-like tumors for the
basal keratins K5 and K6, which are hallmarks of BLBC.
We found that five of seven PDA were positive for K5, and
four of seven were positive for K6. For the spindle tumors,
three of three were positive for both K5 and K6 (Fig. 1e).
Prior to Cre-mediated recombination, the non-
recombined p53lsl_R270H gene acts as a null (−) allele
[11], and the p53lsl_R270H/wt mice are functionally p53−/+
in all tissues (including mammary epithelium). To deter-
mine if the p53lsl_R270H allele was induced through dele-
tion of the Lox-stop-lox cassette via WAP-Cre, we
immunostained tumor sections for p53, which is stabi-
lized by the p53R270H mutation, leading to high expres-
sion. Some tumors were uniformly positive, indicative of
Cre-recombination and p53R270H expression; other tu-
mors were negative or contained areas of p53-positive
cells alongside p53-negative cells, likely reflecting clonal
evolution (Fig. 2a-d). For all experiments (including IHC
in Fig. 1) we only used and compared tumors with high
p53 expression (i.e. expressing the p53R270H allele) in
large areas or throughout the tumor (e.g. Fig. 2c).
Frequent tumor initiating cells (TICs) in poorly
differentiated adenocarcinomas and spindle-like
PtenΔf:p53R270H tumors
One measure for tumor aggressiveness is the frequency
of tumor-initiating cells (TICs), capable of inducing sec-
ondary tumors following transplantation into recipient
mice [25, 26]. PtenΔf:p53R270H tumors from each of the
four different subtypes were dissociated to obtain single
cells, cultured as tumorspheres in ultra-low attachment
plates in serum-free media supplemented with EGF and
FGF, passaged once, and then 1000 or 3500 cells were
injected orthotopically into recipient female mice
(Fig. 3a). While the squamous and AME gave undetect-
able or low TIC frequency of 1/4481, respectively, the
spindle tumors showed TIC frequency of 1/925 and the
PDA tumors an even higher frequency that was not cal-
culatable because all recipient mice developed secondary
lesions (Fig. 3b). Thus, PtenΔf:p53R270H spindle and PDA
tumors exhibit high TIC frequency, indicative of aggres-
sive cancers. Interestingly, histology analysis of second-
ary tumors revealed dominant spindle histology even
when primary lesions were from AME (4/4) or PDAs
(11/16) (Fig. 3c), suggesting that they arose from rare
mesenchymal/spindle subclones within these lesions.
Poorly differentiated and spindle-like PtenΔf:p53R270H
tumors cluster with known mouse models of basal-like
and claudin-low breast cancer
To molecularly classify the PtenΔf:p53R270H spindle and
PDA tumors, we performed unsupervised hierarchical
clustering on six spindle and eight PDA tumors using an
extended intrinsic breast cancer signature [9, 20]. To
compare gene expression across platforms we used the
DWD algorithm [27]. We included several normal mam-
mary glands and MMTV-Her2/Neu tumors as internal
controls. Cluster analysis grouped the normal glands
and tumors with published wild-type mammary gland
and MMTV-Her2/Neu tumors, respectively, thereby
validating our normalization procedure (Fig. 3a). Compar-
ing our mammary tumors to 13 other mouse models
of breast cancer [20], most (4/6) PtenΔf:p53R270H
spindle tumors clustered with other models of spindle
tumors including certain p53-deficient, Brac1/p53-
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Fig. 1 (See legend on next page.)
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deficient and 7,12-dimethylbenzanthracene (DMBA)-
induced mammary tumors (Fig. 4a). We attribute this
incomplete consistency (4/6 rather than 6/6) to intra-
tumor heterogeneity and the distinct biopsies taken
for bioinformatics vs. histology. In contrast, all PDA
(8/8) as well as two spindle-like tumors clustered
most closely, albeit on a separate branch, with SV40
large T antigen-induced tumors, which were previ-
ously shown to resemble human basal-like breast
cancer [20].
Poorly differentiated and spindle-like PtenΔf:p53R270H tumors
cluster with human basal-like and claudin-low breast cancer
We next compared our PtenΔf:p53R270H tumors with the
five human molecular breast cancer subtypes: ERα+ (lu-
minal A and luminal B), HER2, basal-like and claudin-
low breast cancer as well as normal-like tumors [20].
Despite the difficulty in this interspecies analysis, four
mouse PtenΔf:p53R270H spindle tumors clustered with
human claudin-low breast cancer, whereas two tumors
clustered with BLBC. Four of the eight PtenΔf:p53R270H
(See figure on previous page.)
Fig. 1 Pten deletion plus p53-R270H point mutation cooperate to accelerate mammary tumor formation. a Kaplan-Meier mammary tumor-free
curves for WAP-Cre:Ptenfl/fl:p53wt/wt (n = 16; median latency - 413 days), WAP-Cre:Ptenwt/wt:p53R270H/wt (n = 39; median latency - 507 days), and
WAP-Cre:Ptenfl/fl:p53R270H/wt (n = 75; median latency - 291 days) mice. Statistical significance by Wilcoxon method: Pten versus p53, p = 0.0118;
Pten/p53 vs. Pten, p < 0.0001; Pten/p53 vs. p53, p < 0.0001. b Detection of conditional Pten deletion and p53 mutant allele by PCR. c Distribution
of tumor types (%) in WAP-Cre:Ptenfl/fl:p53wt/wt (left; n = 13), WAP-Cre:Ptenwt/wt:p53R270H/wt (middle; n = 9), and WAP-Cre:Ptenfl/fl:p53R270H/wt
(right; n = 76) mice. d Histology of the four major tumor types from WAP-Cre:Ptenfl/fl:p53R270H/wt mice. Original magnification 40×. Larger images
are presented in Additional file 1. e Representative IHC analysis of basal differentiation marker (K14), luminal differentiation marker (K18) and
proliferation marker ki67 in the major tumor types from WAP-Cre:Ptenfl/fl:p53R270H/wt mice. f Representative expression of basal differentiation







Fig. 2 Analysis of mutant p53 accumulation in tumor cells. a-c p53 IHC of WAP-Cre:Ptenfl/fl:p53R270H/wt tumors showing lack of p53 accumulation,
indicating the p53R270H allele was not activated in (a). Arrows and dashed outlines indicate a region with strong p53 accumulation; arrowheads
and dotted outlines to regions with weak or no p53 accumulation (b). Note strong nuclear accumulation of mutant p53 in tumor cells (c). d
Summary of mutant p53 accumulation in the major tumor types in WAP-Cre:Ptenfl/fl:p53R270H/wt mice: mixed, n = 9; squamous, n = 4; AME, n = 9;
spindle, n = 12; PDA, n = 6. AME adenomyoepithelioma, IHC immmunohistochemistry, PDA poorly differentiated adenocarcinoma
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PDAs clustered with human basal-like breast tumors,
whereas four other PDAs clustered with HER2+ breast
cancer (Fig. 4b). We note that in contrast to the original
Herschkowitz et al. article, in which MMTV-Her2/neu
mouse tumors clustered with human luminal breast can-
cer [20], in our classification, the Her2/Neu tumors clus-
tered with human HER2+ breast cancer.
We next used a claudin-low signature developed by
Prat et al. [21] and the GSE18229 dataset, to classify our
PtenΔf:p53R270H tumors with 397 human BC samples.
The data was integrated by DWD and unsupervised
clustering was done by complete linkage analysis. Again,
the four mouse spindle tumors, but not the other (out-
liers) spindle or the eight PDA, clustered with human
claudin-low BC (Fig. 4c). Thus, despite some variations
due to difficulties with batch correction across different
platforms and interspecies analysis as well as intra-
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Fig. 3 High frequency of TICs in PDA and spindle tumors. a Schematic illustration of the experimental design used to analyze TIC frequency in
the four major tumor types. b Tumor-initiating cell (TIC) frequency in the major tumor subtypes in WAP-Cre:Ptenfl/fl:p53R270H/wt mice, showing
high frequency in PDA and spindle tumors. c Histology of secondary tumors showing a selection for spindle-like tumors. For PDAs - 5/16 secondary
tumors remained PDAs, and the rest (11/16) became spindle. For AME tumors, 4/4 secondary were all spindle-like. All primary spindle tumors gave
spindle secondary tumors. AME adenomyoepithelioma, PDA poorly differentiated adenocarcinoma
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Fig. 4 Molecular classification of PD and spindle WAP-Cre:Ptenfl/fl:p53R270H/wt mammary tumors. a Cluster analysis of spindle and PD WAP-
Cre:Ptenfl/fl:p53R270H/wt mammary tumors using an intrinsic gene signature in comparison with 13 other mouse models of breast cancer. b Cluster
analysis of spindle and PDAs WAP-Cre:Ptenfl/fl:p53R270H/wt mammary tumors using an intrinsic gene signature in comparison with human tumor
samples. c Cluster analysis of WAP-Cre:Ptenfl/fl:p53R270H/wt mammary tumors with human claudin-low (green) and basal-like (basal) BC using the
Prat et al. claudin-low signature. BC breast cancer, PDA poorly differentiated adenocarcinoma
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tumors and some of the PDAs clustered with human
claudin-low or BLBC, respectively [20].
Spindle-like PtenΔf:p53R270H mutant and PtenΔf:p53Δf
deletion mammary tumors cluster closely together
We directly compared the expression levels of basal,
luminal and mesenchymal markers, as defined by
Herschkowitz et al., [20] in WAP-Cre:Ptenf/f:p53lsl_R270H/+
mutant spindle and PDA tumors as well as WAP-
Cre:Ptenf/f:p53f/f double-deletion spindle tumors [9]. Clas-
sification analysis with these markers grouped the four
PtenΔf:p53R270H spindle and nearly all (10/11) PtenΔf:p53Δf
spindle tumors together with human claudin-low BC,
whereas six of eight PtenΔf:p53R270H PDA grouped to-
gether with human BLBC (Fig. 5a).
Heat map showing expression of claudins, mesenchymal
and epithelial to mesenchymal transition (EMT) markers
in PtenΔf:p53R270H and PtenΔf:p53Δf spindle tumors is
shown (Fig. 5b). With the exception of the two
PtenΔf:p53R270H outliers, all tumors exhibited low expres-
sion of claudins (claudin 1, 3, 7) and high expression of
EMT markers such as Twist2 and Zeb2. In contrast, N-
cadherin (cdh2) was higher in PtenΔf:p53Δf double-
deletion compared with PtenΔf:p53R270H mutant, whereas
Met gene expression was relatively higher in mutant cells,
suggesting that these tumors are not equally committed to
EMT (see below).
FDA-approved drug screens reveal similar sensitivity of
PtenΔf:p53R270H and PtenΔf:p53Δf claudin-low-like tumors to
8-azaguanine but no differential sensitivity to other drugs
In TNBC, p53 is disrupted by deletions or by mutations
in the DBD [4]. Identification of drugs that can effi-
ciently kill both tumor types or selectively target p53-
deletion vs. p53-mutant-driven breast cancer are there-
fore of great interest. To identify such drugs, we set up a
repurposing screen to identify FDA-approved drugs with
common or differential effects on PtenΔf:p53R270H vs.
PtenΔf:p53Δf tumors. We established and compared
three spindle-like primary PtenΔf:p53R270H and three
PtenΔf:p53Δf tumor cells, using HTP robotic screens of
1120 FDA-approved drugs (Prestwick library). The top
three drugs that most efficiently suppressed all six tumor
lines were the purine analog, 8-azaguanine, the imid-
azole antifungal agent, miconazole, and the dopamine
antagonist, thiethylperazine malate (Fig. 6a). Despite
growing interest in the effect of dopamine antagonists
on cancer stem cells [28], we suspect that the effects of
miconazole and thiethylperazine are not specific because
multiple other imidazoles and dopamine inhibitors
present in our FDA-approved library had much lower, often
agonistic effects on tumor growth (Additional file 2; Discus-
sion). Sensitivity of PtenΔf:p53Δf and PtenΔf:p53R270H tumor
cells to 8-azaguanine was validated on the six lines reveal-
ing IC50 of 0.53 μM (Fig. 6b top; Discussion).
Tumors driven by a p53 DBD mutation are addicted
to its continuous expression [29–31]. Addiction is at
least in part due to mutant p53-mediated transcriptional
activation of the mevalonate pathway, leading to in-
creased sensitivity to statins, which inhibit 3-hydroxy-3-
methyl-glutaryl-CoA (HMG-CoA) reductase, the enzyme
that produces mevalonate [31]. Importantly, depletion of
mutant p53 in these tumors leads to cell demise. This
was observed by knocking down p53 mutant expression
via RNA interference or through HSP90 inhibitors,
which destabilize mutant p53. Accordingly, we found
that knocking down p53R270H protein expression via
lenti-shRNA significantly reduced growth of primary
PtenΔf:p53R270H tumor cells (data not shown). However,
selective inhibition of p53-mutant vs. p53-deleted TNBC
may be achieved not only by destabilizing mutant p53
but also by targeting distinct oncogenic genes/pathways
that cooperate with each p53 allele (i.e. mutation vs. de-
letion). We therefore asked whether any of the 1120
FDA-approved drugs had differential inhibitory effect on
PtenΔf:p53Δf vs. PtenΔf:p53R270H tumor cells. Surpris-
ingly, our screens identified two statins (fluvastatin and
simvastatin) (Fig. 6a), as well as four other drugs (thios-
trepton, podophyllotoxin, parbendazole, mebendazole)
as having differential effects on PtenΔf:p53R270H vs.
PtenΔf:p53Δf. Upon robotic re-screens, PtenΔf:p53Δf
showed increased sensitivity relative to PtenΔf:p53R270H
tumor cells to low concentrations of fluvastatin and
simvastatin but not to the other drugs (Additional
files 3 and 4). This mild increase in sensitivity to sta-
tins was not reproducible or robust enough to show
significance in subsequent validation experiments
(p = 0.3341) (Fig. 6b; bottom). Taken together, using
highly similar PtenΔf:p53Δf vs. PtenΔf:p53R270H
claudin-low like tumor cells we found no robust dif-
ferences in sensitivity to 1120 FDA-approved drugs
(see Discussion).
Claudin-low-like and basal-like PtenΔf:p53R270H tumor cells
have higher metastatic potential than PtenΔf:p53Δf spindle
mammary tumor cells
Results from our cluster analysis and HTP screens sug-
gested that despite the similarity, PtenΔf:p53R270H and
PtenΔf:p53Δf spindle tumors exhibited variances. To ex-
plore such differences further, we performed pathway ana-
lysis using GSEA. Pathways enriched in the PtenΔf:p53Δf
spindle tumors (blue in Fig. 6c) were associated with cell
proliferation and DNA repair/Brca, whereas pathways
induced in PtenΔf:p53R270H spindle tumors (red) were re-
lated to metastasis and other pathways (heat map of se-
lected genes Fig. 6d-f).
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Fig. 5 Molecular clustering of spindle-like PtenΔf:p53R270H and PtenΔf:p53Δf mammary tumors. a Hierarchical clustering using basal, luminal and
mesenchymal genes showing that PtenΔf:p53R270H and PtenΔf:p53Δf spindle tumors grouped together with human claudin-low breast cancer, whereas
PtenΔf:p53R270H PDA and two of the spindle tumors grouped with human basal-like breast cancer. b Heat map showing expression of EMT genes in
spindle-like PtenΔf:p53R270H and PtenΔf:p53Δf tumors. EMT epithelial to mesenchymal transition, PDA poorly differentiated adenocarcinoma
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Fig. 6 (See legend on next page.)
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To functionally test the latter observation, we determined
the metastatic potential of primary PtenΔf:p53R270H spindle-
like and PDA relative to primary PtenΔf:p53Δf spindle tumor
cells using tail vein injection assays. Although this assay does
not monitor invasion and intravasation through the basal
membrane into a blood or lymphatic vessel – it does meas-
ure for the ability of tumor cells to survive in the circulating
system, extravasate and form macrometastases in distal sites,
a rate-limiting step in the metastatic cascade. Following en-
graftment, mice were closely monitored for breathing diffi-
culty, weight loss and sickness. Using these criteria, end
points following transplantation of PtenΔf:p53R270H spindle
and PDA tumor cells were significantly shorter than for
PtenΔf:p53Δf double-deletion tumors (Fig. 7a). Upon autopsy,
lungs from all engrafted mice contained macroscopic nod-
ules, which were confirmed as lung metastases by histo-
logical examination (Fig. 7b-c). Like the TIC assay (Fig. 3),
the lung metastases from spindle tumors invariable shared
the same spindle-shaped morphology as the parental tumors
from which they were derived, whereas primary PDAs gave
rise to metastases that showed either PDA or spindle morph-
ology (Fig. 7d-e). These observations point to subclonal di-
versity/intra-tumor heterogeneity and more efficient
metastasis by PtenΔf:p53R270H spindle tumor cells.
Primary PtenΔf:p53Δf spindle tumors and their metastases
showed near complete absence of the epithelial marker E-
cadherin. In contrast, while PtenΔf:p53R270H primary spindle
tumors were largely negative for E-cadherin, lung metastases
expressed significantly more of this transmembrane glyco-
protein than primary lesions; PDA primary tumors were
positive for E-cadherin to varying degrees, and this was
largely preserved in metastatic counterparts (Fig. 7f-g). While
E-cadherin expression increased in PtenΔf:p53R270H metasta-
ses, expression of the mesenchymal marker vimentin was re-
duced (Fig. 7g, Additional file 5). Together these results
suggest that increased metastatic potential of PtenΔf:p53R270H
relative to PtenΔf:p53Δf tumors may be attributed at least in
part to their ability to undergo partial mesenchymal to epi-
thelial (MET) conversion, which is required for efficient
colonization and growth at distal sites [32].
Discussion
We show that targeted deletion of the tumor suppressor
Pten together with expression of a p53 DBD mutant,
R270H, in mammary epithelium via WAP-Cre induces di-
verse mammary tumor subtypes including PDA and spin-
dle tumors. Intra- and inter-species cluster analysis
classified most PDA and spindle tumors as basal-like and
claudin-low like TNBC, respectively. In stark contrast,
double-deletion tumors from WAP-Cre:Ptenf/f:p53f/f mice
invariably cluster with human claudin-low breast cancer
[9]. Claudin-low-like TNBC were also found when Pten
and p53, or Rb plus p53 were homozygously deleted via
MMTV-Cre [9, 17], or when the MET oncogene was
overexpressed in mammary epithelium together with
homozygous p53 deletion [33]. Indeed, these articles
showed that homozygous loss of p53 alone induces
many, though not exclusively, claudin-low-like tu-
mors, indicating that deletion of this tumor suppres-
sor in the mouse directs tumorigenesis toward this
subtype. The PtenΔf:p53R270H PDAs expressed the
basal keratins K5 and K6, clustered with mouse models of
BLBC and with human BLBC samples, exhibited high TIC
frequency, and readily formed lung metastases following
tail vein injections. Thus, WAP-Cre:Ptenf/f:p53lsl_R270H/+
mice offer a new model to study basal-like as well as
claudin-low Pten/p53-deficient TNBC. Our results also
suggest that WAP-Cre:p53lsl_R270H/+ rather than WAP-
Cre:p53f/f mice should be used to model human breast
cancer in conjunction with mutations in other breast can-
cer drivers.
PtenΔf:p53Δf and PtenΔf:p53R270H tumors provide the
means to compare histologically indistinguishable tu-
mors with either mutation of deletion of p53. We there-
fore performed FDA-approved drug screens to identify
compounds that can kill both tumors or preferentially
target tumors driven by p53 deletion or mutation. We
found that 8-azaguanine, a purine analog, efficiently
killed both PtenΔf:p53Δf and PtenΔf:p53R270H tumors.
Sensitivity to 8-azaguanine may reflect high cell prolifer-
ation or low levels of guanine deaminase, which can
convert this purine analog to a noncytotoxic metabolite
(8-azaxanthine) [34]. 8-azaguanine incorporation via hypo-
xanthine guanine phosphoribosyl transferase (HGPRTase)
leads to inhibition of purine nucleotide synthesis. It may
also be toxic due to its incorporation into RNA [35]. Des-
pite some benefits to leukemia patients, adverse dermato-
logical reactions, nausea and vomiting limit its use [36].
(See figure on previous page.)
Fig. 6 HTP screens and GSEA reveal similarities and differences between PtenΔf:p53R270H and PtenΔf:p53Δf mammary tumors. a Average response of three
independent primary tumor lines from WAP-Cre:Ptenfl/fl:p53R270H/wt mice vs. three independent primary tumor lines from WAP-Cre:Ptenfl/fl:p53fl/fl mice to
1120 FDA-approved small molecules. Highlighted are C (no cells negative control), 8-azaguanine, miconazole, thiethylperazine malate, fluvastatin and
simvastatin. b Dose–response curves for 8-azaguanine (average IC50 = 0.53 μM; top) and fluvastatin (IC50 = 0.52 μM for mutant lines; IC50 = 0.34 μM for
deletion lines; bottom) using MTT viability assay. c GSEA showing selected pathways enriched in claudin-low-like WAP-Cre:Ptenfl/fl:p53R270H/wt (red) versus
pathways enriched in WAP-Cre:Ptenfl/fl:p53wt/wt (blue) tumors. Green lines connect overlapping pathways. Proliferation and metastasis pathways are
highlighted. d-f Heat map showing expression of metastasis (d), proliferation (e) and DNA repair (d) genes in PtenΔf:p53R270H vs. PtenΔf:p53Δf spindle-like
tumors. HTP high-throughput, GSEA, gene set enrichment analysis






Fig. 7 (See legend on next page.)
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Additional analysis is required to assess possible benefits, if
any, of 8-azaguanine either alone or in combination with
PI3K antagonists or other inhibitors for Pten/p53-deficient
TNBC. Notably, in a kinome screen of PtenΔf:p53Δf tumors
we identified eEF2K antagonists as better inhibitors than
AKT and PI3K inhibitors [9]. Such pathway-specific drugs
are much more likely to have a large therapeutic window as
compared to cytotoxic drugs like 8-azaguanine. Additional
screens with both PtenΔf:p53Δf and PtenΔf:p53R270H tumors
as well as with human Pten/p53-deficient breast cancer
lines using large libraries of divergent compounds may un-
cover new potent drugs for this aggressive cancer subtype.
Contrary to published results on increased sensitivity of
mutant p53 to statins [31], we observed consistent but
mild and statistically insignificant increase in sensitivity of
PtenΔf:p53Δf tumor cells to HMG-CoA inhibitors relative
to PtenΔf:p53R270H tumor cells. One explanation for this
discrepancy may be that although p53 mutation alone in-
creases sensitivity to statins by inducing the mevalonate
pathway, tumors that develop in the absence of p53 (p53
deletion) may increase sensitivity to statins through other
mechanisms. Indeed, we found that a signature that pre-
dicts sensitivity to statins [37] is elevated in PtenΔf:p53Δf
relative to PtenΔf:p53R270H tumor cells (not shown). We
note that the FDA-approved drug library we used here
does not include the HSP90 inhibitor geldanamycin or its
more potent derivatives, which destabilize mutant p53.
However, we found that knockdown of p53R270H protein
impeded cell growth (not shown) indicating that
PtenΔf:p53R270H tumor cells are addicted to continuous
expression of mutant p53.
Despite – and perhaps because of – the inter- and intra-
tumor heterogeneity seen in WAP-Cre:Ptenf/f:p53lsl_R270H/+
mice, they offer certain advantages over WAP-
Cre:Ptenf/f:p53f/f mice. First, they develop PDA/basal-
like tumors in approximately 10 % of mice and spindle/
claudin-low-like tumors in approximately 30 % of mice.
Tumor-bearing animals can be biopsied to determine hist-
ology and then treated with candidate drugs, allowing
their effect to be tested on diverse tumor types with simi-
lar oncogenic initiation events (Pten loss; p53 mutation).
Alternatively, as described herein, tumors can be har-
vested, frozen, classified and then transplanted to obtain
multiple xenografts with uniform tumor subtype. To-
gether, the WAP-Cre:Ptenf/f:p53lsl_R270H/+ and WAP-
Cre:Ptenf/f:p53f/f mice model the spectrum of p53 gene
aberrations and Pten loss seen in human TNBC.
Using GSEA and functional analysis we showed that
PtenΔf:p53R270H tumor cells are more metastatic than
PtenΔf:p53Δf tumors and this was correlated with in-
duction of E-cadherin in lung metastases from
PtenΔf:p53R270H tumor cells. P53 mutations in the DBD
were shown to increase metastasis through induction of
EMT via several routes including sequestration of p63,
stabilization/activation of SLUG/SNAIL, induction of the
mir130b-Zeb1 axis, TWIST and SLUG transcription fac-
tors and other mechanisms [12, 38–42]. Our study sug-
gests that once disseminating mutant p53 tumors home at
distal sites, they more readily undergo MET, which en-
hances colonization, the dominant rate-limiting step of
the metastatic cascade [32, 43, 44].
Conclusions
WAP-Cre:Ptenf/f:p53lox.stop.lox_R270H/+ mice described herein
together with WAP-Cre:Ptenf/f:p53f/f mice [9], provide
powerful preclinical models to interrogate and decipher the
genetic cooperation that drive primary basal-like and
claudin-low TNBC development and metastatic spread/
colonization, as well as identify and test for novel therapeu-
tics that target these aggressive breast cancers.
Additional files
Additional file 1: Representative large images of histology of
primary WAP-Cre:Ptenfl/fl:p53R270H/wt mammary tumors shown in
Fig. 1. (PPT 1510 kb)
Additional file 2: Z scores for response to dopamine antagonist
(amoxapine, clomipramine hydrochloride, clozapine, domperidone
maleate, droperidol, metoclopramide monohydrochloride,
risperidone, thiethylperazine malate, thioridazine hydrochloride,
trifluoperazine dihydrochloride, and trimipramine maleate salt) and
imidazole antifungal (butoconazole nitrate, clotrimazole, econazole
nitrate, isoconazole, ketoconazole, miconazole, sertaconazole
(See figure on previous page.)
Fig. 7 WAP-Cre:Ptenfl/fl:p53R270H/wt spindle and PDA tumor cells exhibit higher metastatic potential than WAP-Cre:Ptenfl/fl:p53fl/fl spindle tumor
cells. a Kaplan-Meier survival curve of NOD/SCID female mice following tail vein injection with indicated primary tumor cells showing that
p53R270H mutation accelerated metastatic formation relative to p53 deletion. Mice were euthanized when moribund. Statistical significance by
Wilcoxon method: spindle Ptenfl/fl/p53fl/fl vs. spindle Ptenfl/fl/p53R270H, p = 0.0004; spindle Ptenfl/fl/p53fl/fl vs. PDA Ptenfl/fl/p53R270H, p = 0.0012;
spindle Ptenfl/fl/p53R270H vs. PDA Ptenfl/fl/p53R270H, p = 0.16. b-e. Representative whole lung (b) and H&E images (c) of mice injected with
WAP- Cre:Ptenfl/fl:p53R270H/wt mammary tumor cells at end point. Arrowheads indicate metastatic lesions. Representative H&E images of (d)
primary spindle and (e) primary PDA WAP-Cre:Ptenfl/fl:p53R270H/wt mammary tumors and their metastatic counterparts. Note that one of the
metastatic lesions from the PDA had spindle-shaped morphology (bottom right). f Representative images of E-cadherin expression in primary
WAP-Cre:Ptenfl/fl:p53R270H/wt and WAP-Cre:Ptenfl/fl:p53fl/fl mammary tumors and lung metastases. g Expression levels of epithelial (E-cadherin) and
mesenchymal (vimentin) markers in primary WAP-Cre:Ptenfl/fl:p53R270H/wt and WAP-Cre:Ptenfl/fl:p53fl/fl mammary tumors and lung metastases. H&E
hematoxylin and eosin, PDA poorly differentiated adenocarcinoma
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nitrate, and sulconazole nitrate) treatment of three independent
primary WAP-Cre:Ptenfl/fl:p53R270H/wt tumor lines and three
independent primary WAP-Cre:Ptenfl/fl:p53fl/fl tumor lines.
(PPT 102 kb)
Additional file 3: Dose–response curves for fluvastatin and simvastatin
in three independent primary WAP-Cre:Ptenfl/fl:p53R270H/wt tumor lines
and three independent primary WAP-Cre:Ptenfl/fl:p53fl/fl tumor lines.
Insignificant P values for both curves. In addition, for simvastatin, when
the six lines were analyzed independently, IC50 for the three mutant lines
were: 2.829, 2.474 and 0.1096; IC50 for the three deletion lines were:
0.01233, 0.1911 and 0.01995. P value of these six IC50 values was 0.18.
(PPT 108 kb)
Additional file 4: Dose–response curves for thiostrepton,
podophyllotoxin, mebendazole and parbendazole in three
independent primary WAP-Cre:Ptenfl/fl:p53R270H/wt tumor lines and
three independent primary WAP-Cre:Ptenfl/fl:p53fl/fl tumor lines.
Insignificant P values for all curves. (PPT 930 kb)
Additional file 5: Representative images of vimentin
immunostaining of primary WAP-Cre:Ptenfl/fl:p53R270H/wt and
WAP-Cre:Ptenfl/fl:p53fl/fl mammary tumors and lung metastases
(quantification in Fig. 7). (PPT 930 kb)
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